within Pharmacolibrary.Drugs.C_CardiovascularSystem.C05B_AntivaricoseTherapy.C05BA51_HeparinoidCombinations;

model HeparinoidCombinations
  extends Pharmacolibrary.Drugs.ATC.C.C05BA51;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C05BA51</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Heparinoid combinations are medicinal products containing mixtures of heparinoids, which are glycosaminoglycan-like substances with anticoagulant and anti-inflammatory effects. These combinations are often used topically for the treatment of varicose veins, superficial thrombophlebitis, bruises, and hematomas. They are available primarily as over-the-counter or prescription topical gels and creams in various countries. The systemic use of heparinoid combinations is limited, and such products are not a mainstay of anticoagulant therapy; topical use is still approved in some local markets.</p><h4>Pharmacokinetics</h4><p>No direct human pharmacokinetic data for topical heparinoid combinations (ATC code C05BA51) could be identified in peer-reviewed publications. Pharmacokinetics are presumed from limited systemic absorption studies in healthy adults after topical administration.</p><h4>References</h4><ol><li><p>Ohtani, M, et al., &amp; Iga, T (2002). [Effect of admixture of commercially available corticosteroid ointments and/or creams on vasoconstrictor activity]. <i>Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan</i> 122(1) 107â€“112. DOI:<a href=\"https://doi.org/10.1248/yakushi.122.107\">10.1248/yakushi.122.107</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11828745/\">https://pubmed.ncbi.nlm.nih.gov/11828745</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end HeparinoidCombinations;
